Peripheral artery disease in peritoneal dialysis and hemodialysis patients: single-center retrospective study in Taiwan by Chun-Chuan Lee et al.
Lee et al. BMC Nephrology 2012, 13:100
http://www.biomedcentral.com/1471-2369/13/100RESEARCH ARTICLE Open AccessPeripheral artery disease in peritoneal dialysis and
hemodialysis patients: single-center retrospective
study in Taiwan
Chun-Chuan Lee1, Chih-Jen Wu2,4, Li-Hua Chou3, Su-Mei Shen3, Sheng-Fang Chiang3, Pi-Chu Jen3,
Mei-Ching Yeh3 and Chi-Feng Pan2,5*Abstract
Background: Peripheral artery disease (PAD) is a condition characterized by restricted blood flow to the
extremities, and is especially common in the elderly. PAD increases the risk for mortality and morbidity in patients
with end-stage renal disease (ESRD), especially those on hemodialysis (HD).
Methods: The records of 484 patients with end-stage renal disease who were on HD or peritoneal dialysis (PD)
were reviewed. PAD was diagnosed based on the ankle-brachial pressure index (ABI). Demographic and clinical
characteristics were analyzed.
Results: PAD had an overall prevalence of 18.2% and was significantly more common in HD patients (21.8%) than
in PD patients (4.8%). Advanced age, diabetes mellitus, smoking, low parathyroid hormone level, elevated serum
ferritin, elevated serum glucose, and low serum creatinine levels increased the risk for PAD. PAD was independently
associated with advanced age, diabetes mellitus, duration of dialysis, low serum creatinine, and hyperlipidemia. PD
patients had a significantly lower prevalence of PAD than HD patients, maybe due to their younger age and lower
prevalence of diabetes mellitus in this present study.
Conclusions: The prevalence of PAD was greater in the HD group than the PD group. Most of the risk factors for
PAD were specific to HD, and no analyzed factor was significantly associated with PAD in PD patients.
Keywords: Ankle-brachial pressure index (ABI), Cardiovascular disease, End-stage renal disease, Hemodialysis,
Peritoneal dialysis, Peripheral artery diseaseBackground
Cardiovascular disease is the most common cause of
death in patients with end-stage renal disease (ESRD)
[1]. Peripheral artery disease (PAD) is an important mar-
ker of systemic atherosclerosis, and often leads to signifi-
cant morbidity and mortality, particularly in patients
with ESRD [2]. The National Health and Nutrition
Examination Survey (NHANES) of 1999–2000 reported
that PAD affects approximately 5 million adults, includ-
ing 12-20% of Americans aged 65 years and older [3].
The prevalence of PAD increases dramatically with age,* Correspondence: pan530319@yahoo.com.tw
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reproduction in any medium, provided the orbut the actual prevalence may be underestimated.
Experts have estimated that PAD affects approximately 8
million people in the U.S. alone [4]. In contrast, little is
known about the prevalence of PAD in Asian ESRD
patients.
Despite the high prevalence of PAD and its association
with increased cardiovascular disease, few PAD patients
are given treatment for this condition, because most are
asymptomatic [5]. PAD often progresses silently until
the onset of the most common symptom, intermittent
claudication [2]. However, in the general population,
only about 10% of patients with PAD develop this classic
symptom, about 40% have no complaint of leg pain, and
about 50% have diverse leg symptoms that are not typ-
ical of classic claudication [4].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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otic disease. Patients with PAD have a four-to-five fold
greater risk of dying from a cardiovascular event and a
two-to-three fold higher overall mortality rate relative to
patients without PAD [6]. The irreversible and reversible
risk factors associated with PAD are similar to those for
ischemic heart disease [7]. Although younger patients
represent a small percentage of PAD cases, they have
poorer long-term outcome and experience more compli-
cations associated with bypass revascularization surgery
[6]. There is a remarkably high prevalence of PAD in
patients with renal insufficiency [8]. In particular, 24% of
the NHANES population older than 40 years with renal
insufficiency had PAD, but only 3.7% with normal renal
function had PAD, and this association was independent
of diabetes, hypertension, and age [8].
Increased duration of dialysis and conventional cardio-
vascular disease risk factors (other than hypertension and
hyperlipidemia) are known risk factors for PAD [8]. PAD
has been diagnosed in 25.3% of ESRD patients, and the
prevalence varied widely among different populations [5].
A recent study of patients on maintenance ambulatory
peritoneal dialysis (PD) indicated the prevalence of PAD
was 27.4% of all patients, and was 45% in patients older
than 70 years [9].
The ankle-brachial pressure index (ABI) is the sim-
plest, least expensive, and most reliable method of
detecting atherosclerosis in asymptomatic individuals
with suspected PAD [10]. Numerous clinical and epi-
demiological studies have used the ABI to screen for
PAD because PAD of the lower extremities is associated
with poor overall prognosis [11,12]. In the U.S., the
prevalence of PAD is much higher in patients on
hemodialysis (HD) than in age- and sex-matched healthy
subjects [11]. A Finnish study indicated the prevalence
of an elevated ABI was 8.4% among patients referred for
vascular consultation and that PAD was much more
common in patients with renal failure [13]. However,
there is little available data on relationship of PAD and
renal failure in Asian populations, and fewer data in PD
patients.
In the present study, we compared HD and PD
patients who were receiving maintenance dialysis in the
Mackay Memorial Hospital (Taipei, Taiwan) to identify
the prevalence and risk factors associated with PAD in
ESRD patients and to compare prevalence and risk of
PAD in HD and PD patients.
Methods
Between June 1, 2007 and September 30, 2007, 529
patients with ESRD were on maintenance dialysis in the
Dialysis Unit of Mackay Memorial Hospital. A total of
45 patients had severe illnesses, such as liver cirrhosis,
malignancies, apparent acute inflammatory diseases, oramputation of both legs and were excluded. ABI was
recorded for the remaining 484 patients, which included
380 HD patients (all with synthetic membranes) and 104
PD patients (median [IQR] urea clearance, 2.27 L/Day
[0–20.52]). The Institutional Review Board of Mackay
Memorial Hospital approved this retrospective study of
the records of these patients. All patients had undergone
dialysis for at least 3 months prior to enrollment.
The following basic data was recorded for all subjects at
baseline: age, gender, height, weight, BMI (kg/m2), and
duration and mode of dialysis. Analysis of risk factors
associated with PAD considered the effect of smoking
(ever versus never), cardiovascular or cerebrovascular dis-
ease (CVD), hypertension, diabetes, hyperlipidemia, and
underlying renal disease. Dialysis dose was calculated from
Daugirdas formula for Kt/V and serum assays were per-
formed for intact parathyroid hormone (iPTH),
hematocrit (Hct), fasting glucose, blood urea nitrogen
(BUN), creatinine (Cr), calcium (Ca), phosphorus (P), cal-
cium and phosphorus product (Ca×P), albumin, choles-
terol, triglyceride (TG), total carbon dioxide (TCO2), and
ferritin. Both groups were given the minimal recom-
mended doses of dialysis and the presented Kt/V results
indicate the Kt/V per dialysis session.
The ABI ratio was calculated with the Fukuda Vas-
cular Screening system (VaSera VS-1000™, Fukuda
Denshi Co., Ltd., Tokyo, Japan) and were performed
while the subjects were supine. Systolic blood pres-
sure was measured at the brachial artery on the
nondialytic vascular access arm and on both ankles
(at the posterior tibial arteries). PAD was diagnosed
if ABI was less than 0.9 in either lower extremity. A
patient was assigned a score of “PAD-one” if the
ABI was low in one lower extremity and a score of
“PAD-two” if the ABI was low in both lower
extremities.
Statistical analysis
For continuous variables, data are presented as means ±
standard deviations (SDs) and an independent two-
sample t-test was used to compare the HD and PD
groups. If variables were not normally distributed, data
is presented as medians and interquartile ranges (IQRs)
and the Mann–Whitney U test was used for compari-
sons. For categorical variables, data are presented as
number (percentage) and the Chi-square test was used
for comparisons of the two binary variables. Logistic re-
gression analysis was used to identify factors related to
the presence of PAD. Variables associated with PAD
based on univariate analysis were entered into multivari-
ate models. All statistical assessments were two-sided
and a p-value less than 0.05 was considered significant.
Statistical analyses were performed using SPSS 15.0
(SPSS Inc., Chicago, IL).
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Table 1 shows the demographic and clinical characteris-
tics of the 484 ESRD patients who were on HD or PD in
the dialysis unit of Mackay Memorial Hospital from June
1, 2007 to September 30, 2007. There were 213 males
and 271 females, the mean age was 57.91 ± 13.64 years
(range: 21 to 90 years), and there were 380 patients
undergoing HD (78.5%) and 104 patients undergoing PD
(21.5%). The overall prevalence of PAD was 18.2%
(n = 88). There were statistically significant differences
between the two groups with regard to age (HD: 60.39 ±
12.81 years, PD: 48.87 ± 12.76 years, p<0.001), median
duration of dialysis (HD: 55 months, PD: 36 months,
p<0.001), history of DM (HD: 36.6%, PD: 18.3%,
p<0.0001), smoking status (HD: 36.6%, PD: 14.4%,







Duration of Dialysis (months)3 48 (26, 88)
DM, n (%)2 158 (32.6)
HT, n (%)2 356 (73.6)
Hyperlipidemia, n (%)2 199 (41.1)









Albumin (g /dL)1 3.94±0.38
i-PTH (pg/ mL)3 284.8 (163.4, 480.7) 2
Ferritin (ng/ mL)3 573.0 (364.0, 761.7) 6
Cholesterol (mg/dL)3 183 (154, 209)
TG (mg/ dL)3 125 (82, 195)
Fasting blood sugar (mg/dL)3 95 (83, 117)
Cr (mg/dL)1,4 11.01±2.77




* significant difference between groups (p<0.05).
P-values were calculated by: 1Independent two sample t-test (mean ± SD); 2Chi-squ
measured pre-dialysis.21.8%, PD: 4.8%). The prevalence of PAD in one extrem-
ity (HD: 11.8%, PD: 1.9%) and in two extremities (HD:
10.0%, PD: 2.9%) were greater in the HD group
(p<0.001) In addition, the HD group had significantly
higher levels of Hct, albumin, ferritin, uric acid (p<0.05
for all) and significantly lower levels of Kt/V per dialysis
session, TCO2, cholesterol, blood sugar, Cr, Ca, P and
Ca×P (p<0.05 for all).
Figure 1 shows the frequency distributions of our ABI
measurements. There were no significant differences in
the mean ± SD of the left and right ABI among HD
patients or in the mean ± SD of the left and right ABI
among PD patients. However, HD patients had a signifi-
cantly lower mean ABI (p = 0.047).
Table 2 shows the demographic and clinical character-
istics of ESRD patients with and without PAD. PADysis (HD) and peritoneal dialysis (PD) patients (n = 484)
HD group (n=380) PD group (n=104) P-value
60.39±12.81 48.87±12.76 <0.001*
0.131
174 (45.8) 39 (37.5)
206 (54.2) 65 (62.5)
22.44±3.34 22.67±3.77 0.533
55 (31, 94) 36 (14, 57) <0.001*
139 (36.6) 19 (18.3) <0.001*
280 (73.7) 76 (73.1) 0.901
149 (39.2) 50 (48.1) 0.103
109 (28.7) 15 (14.4) 0.003*
<0.001*
297 (78.2) 99 (95.2)
45 (11.8) 2 (1.9)





81.7 (166.2, 468.9) 328.9 (160.7, 512.0) 0.541
32.8 (487.5, 799.6) 330.7 (173.1, 482.1) <0.001*
179 (151, 205) 190 (172, 213) 0.012*
124 (82, 194) 130 (82, 232) 0.372






are test (number [percentage]); 3Mann-Whitney U test (median [IQR]); 4Cr was
Figure 1 Distribution of ABI measurements on the right and left side of hemodialysis patients (A and B) and peritoneal dialysis
patients (C and D).
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(61.4% vs 26.3%, p<0.001), older (68.66 ± 10.54 years vs
55.52 ± 13.10 years, p <0.001), smoke (35.2% vs 23.5%,
p = 0.022). Patients without PAD had higher levels of
serum albumin, i-PTH, and Cr (p<0.05 for all) and
patients with PAD had higher levels of ferritin and blood
sugar (p<0.05 for both).
Table 3 shows the results of univariate and multivari-
ate logistic regression analysis of factors associated
with PAD in all of the maintenance dialysis patients.
Univariate analysis indicated that age, type of dialysis,
DM, smoking, albumin, i-PTH, ferritin, blood sugar,
and Cr were significantly associated with PAD (p<0.05
for all). After controlling for age and DM history,
multivariate logistic regression analysis indicated that
for each 1 mg/dL elevation of Cr, the odds for PAD
were 15% lower (OR = 0.85; 95% C.I. = 0.74 to 0.98;
p = 0.024).Next, we used the same univariate and multivariate
methods to separately analyze the risk factors for PAD
in HD patients (Table 4) and PD patients (Table 5).
Among HD patients, advanced age and history of DM
were independently associated with PAD. Among PD
patients, there were no factors significantly associated
with PAD.
Discussion
We determined the prevalence of PAD in 484 Taiwan-
ese ESRD patients from a single medical center and
compared the characteristics of patients who were on
HD with those on PD. Our results indicate that
advanced age, presence of diabetes mellitus, and low
serum creatinine were independently associated with
the presence of PAD. Advanced age was the most sig-
nificant risk factor for PAD (NonPAD: 55.52 ± 13.10,
PAD: 68.66 ± 10.54, p < 0.001). The inverse
Table 2 Clinical and demographic characteristics of all maintenance dialysis patients with and without peripheral
arterial disease (PAD) (n = 484)
Variables Non-PAD (n=396) PAD (n=88) P-value
Age (years)1 55.52±13.10 68.66±10.54 <0.001*
Gender, n (%)2 0.136
Male 168 (42.4) 45 (51.1)
Female 228 (57.6) 43 (48.9)
BMI (kg/m2)1 22.53±3.56 22.30±2.82 0.566
Type of dialysis, n (%)2 <0.001*
HD 297 (75.0) 83 (94.3)
PD 99 (25.0) 5 (5.7)
Duration of Dialysis(months)3 47 (25, 86) 57 (27, 96) 0.318
DM, n (%)2 104 (26.3) 54 (61.4) <0.001*
HT, n (%)2 292 (73.7) 64 (72.7) 0.846
Hyperlipidemia, n (%)2 158 (39.9) 41 (46.6) 0.248
Smoking, n (%)2 93 (23.5) 31 (35.2) 0.022*
Daugirdes Kt/V1 1.91±0.39 1.85±0.46 0.218
Hct (%)1 30.02±4.50 30.44±3.66 0.418
TCO2 (mmol/L)
1 23.55±2.95 23.51±2.45 0.897
Albumin (g /dL)1 3.96±0.38 3.84±0.38 0.012*
i-PTH (pg/ mL)3 309.1(173.1, 497.8) 223.6 (101.8, 385.6) 0.002*
Ferritin (ng/ mL)3 559.2 (354.0, 754.3) 651.3 (479.1, 846.8) 0.017*
Cholesterol (mg/dL)3 183 (154.5, 204.5) 178 (150, 216) 0.915
TG (mg/ dL)3 122 (82, 192) 137 (81, 213) 0.398
Blood sugar (mg/dL)3 93 (82, 112) 107 (85, 159) <0.001*
Cr (mg/dL)1 11.38±2.67 9.33±2.61 <0.001*
Uric Acid (mg/dL)1 7.27±1.29 7.05±1.33 0.142
Ca (mg/dL)1 9.07±0.84 9.07±0.78 0.990
P (mg/dL)1 5.46±1.35 5.16±1.51 0.064
Ca×P (mg/dL)1 49.66±13.42 46.84±14.47 0.081
* significant difference between groups (p < 0.05).
P-values were calculated by: 1Independent two sample t-test (mean ± SD); 2Chi-square test (number [percentage]); and 3Mann-Whitney U test (median [IQR]).
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intuitive. We suggest that this may be due to the lower
muscle mass or frailty of these patients. The higher
serum Ca, P, and Ca×P were all significantly higher in
PD patients, possibly because HD patients were usually
on more restrictive diets.
Previous studies of Western populations indicated that
PAD is much more common in patients with ESRD
(17-48%) than in the general population [14]. The docu-
mentation of declining ABI measurements in patients
with suspected or known PAD can be an effective way
to chart the patient prognosis. Previous studies indicated
that this test has a sensitivity greater than 90% and a
specificity of 95% for the diagnosis of PAD [15,16]. In
particular, one study of 606 patients (mean age: 62years;
68% male) reported that major one-year decline in rest-
ing and post-exercise ABI were associated with all-causemortality, cardiac events, stroke, kidney failure, and
PAD [17].
Our study and other studies of PAD examined patients
undergoing HD. However, a previous study of Spanish
patients with chronic renal failure stages IV and V who
were not undergoing dialysis reported that 19% of
patients had PAD or other vascular pathologies and that
the 5-year mortality rate was higher in patients with
PAD than in those without PAD (64% vs. 20%) [18]. In
addition, a previous study of Japanese subjects with type-
2 diabetes mellitus who were not undergoing HD
reported that chronic kidney disease had a more signifi-
cant impact on PAD than metabolic syndrome [19]. Fi-
nally, a study of U.S. subjects with no renal abnormalities
(participants in the Iron [Fe] and Atherosclerosis Study
Study [FeAST], Veterans Affairs [VA] Cooperative Study
[CSP] #410) reported significant associations between
Table 3 Univariate and multivariate logistic regression
analysis of risk factors associated with PAD in all
maintenance dialysis patients (n = 484)
Variables Univariate Multivariate
OR (95% C.I.) OR (95% C.I.) P-value
Age 1.09 (1.07, 1.12)* 1.08 (1.05, 1.11) <0.001*
Gender
Male vs. Female 1.42 (0.89, 2.26)
BMI 0.98 (0.92, 1.05)
Type of dialysis
HD vs. PD 5.53 (2.18, 14.04)* 1.83 (0.64, 5.21) 0.258
Duration of Dialysis 0.99 (0.99, 1.01)
DM
Yes vs. No 4.46 (2.74, 7.24)* 2.88 (1.58, 5.25) 0.001*
HT
Yes vs. No 0.95 (0.57, 1.60)
Hyperlipidemia
Yes vs. No 1.31 (0.83, 2.09)
Smoking
Yes vs. No 1.77 (1.08, 2.91)* 1.37 (0.74, 2.54) 0.322
Daugirdes Kt/V 0.68 (0.36, 1.26)
Hct 1.02 (0.97, 1.08)
TCO2 1.00 (0.92, 1.08)
Albumin 0.47 (0.26, 0.85)* 0.98 (0.45, 2.17) 0.963
i-PTH 0.98 (0.97, 0.99)* 0.99 (0.98, 1.01) 0.307
Ferritin 1.00 (1.00 1.01)* 1.00 (0.99, 1.01) 0.706
Cholesterol 1.00 (0.99, 1.01)
TG 1.00 (0.99, 1.01)
Blood sugar 1.00 (1.00, 1.01)* 1.00 (0.99, 1.01) 0.383
Cr 0.72 (0.65, 0.80)* 0.85 (0.74, 0.98) 0.024*
Uric Acid 0.87 (0.73, 1.05)
Ca 1.00 (0.76, 1.33)
P 0.85 (0.71, 1.01)
Ca×P 0.99 (0.97, 1.01)
* Statistically significant (P<0.05).
Table 4 Univariate and multivariate logistic regression
analysis of risk factors associated with peripheral artery
disease (PAD) in hemodialysis (HD) patients (n = 380)
Variables Univariate Multivariate
OR (95% C.I.) OR (95% C.I.) P-value
Age 1.10 (1.07, 1.13)* 1.09 (1.06, 1.13) <0.001*
Gender
Male vs. Female 1.36 (0.84, 2.22)
BMI 0.99 (0.92, 1.07)
Duration of Dialysis 0.99 (0.99, 1.01)
DM
Yes vs. No 4.05 (2.43, 6.74)* 3.36 (1.80, 6.25) <0.001*
HT
Yes vs. No 1.07 (0.61, 1.87)
Hyperlipidemia
Yes vs. No 1.42 (0.87, 2.31)
Smoking
Yes vs. No 1.46 (0.87, 2.45)
Daugirdes Kt/V 1.15 (0.58, 2.26)
Hct 1.01 (0.95, 1.07)
TCO2 1.17 (1.02, 1.30)* 0.98 (0.85, 1.14) 0.832
Albumin 0.33 (0.17, 0.65)* 0.99 (0.43, 2.27) 0.981
i-PTH 0.99 (0.98, 1.00)* 1.00 (0.99, 1.00) 0.213
Ferritin 1.00 (0.99, 1.01)
Cholesterol 1.00 (0.99, 1.01)
TG 1.00 (0.99, 1.01)
Blood sugar 1.00 (1.00, 1.01)* 1.00 (0.99, 1.01) 0.322
Cr 0.73 (0.65, 0.82)* 0.86 (0.74, 1.01) 0.059
Uric Acid 0.81 (0.67, 0.99)* 1.06 (0.83, 1.37) 0.626
Ca 1.14 (0.83, 1.55)
P 0.92 (0.77, 1.10)
Ca×P 0.99 (0.98, 1.01)
* Statistically significant (p<0.05).
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and mortality in patients with PAD [20].
Another interesting finding of the present study is that
the risk factors for PAD were different in HD patients
and PD patients. In particular, pooling all patients to-
gether indicated that the risk factors for PAD were simi-
lar to those reported in the literature (Table 3). However,
separate analysis of the two groups indicated that the
risk factors in the HD group remained almost the same
as for all patients (Table 4), but that there were no sig-
nificant risk factors for the PD patients (Table 5). This
indicates that further study of additional factors may beneeded to better understand the risk for PAD in PD
patients.
Our study has several limitations. First, this was a
retrospective study, so there may have been errors due
to confounding and bias. Second, the study period was
only four months, so we cannot make any conclusions
about the long-term outcomes. Third, all of our patients
were from a single medical center in Taiwan, so our
results may not be generalizable to other medical centers
in Taiwan or elsewhere. Fourth, our use of ABI for diag-
nosis of PAD may have led to some misdiagnosis in
patients with vessel calcification, leading to false negative
diagnoses (type II errors). This limitation could have
been overcome by use of toe plethysmography. Finally,
we had no records of C-reactive protein, and use of
Table 5 Logistic regression analysis of risk factors
associated with peripheral artery disease (PAD) in
peritoneal dialysis (PD) patients (n = 104)
Variables Univariate
OR (95% C.I.)
Age 1.03 (0.96, 1.10)
Gender
Male 1.12 (0.18, 6.70)
Female 1.00
BMI 0.90 (0.69, 1.18)
Duration of Dialysis 1.00 (0.98, 1.02)
DM
No 1.00
Yes 3.22 (0.50, 20.74)
HT
No 1.00
Yes 0.23 (0.04, 1.43)
Hyperlipidemia
No 1.00
Yes 1.66 (0.27, 10.37)
Smoking
No 1.00
Yes 4.41 (0.67, 28.96)
Daugirdes Kt/V 1.44 (0.17, 12.15)
Hct 1.02 (0.82, 1.21)
TCO2 1.02 (0.72, 1.45)
Albumin 0.46 (0.06, 3.80)
i-PTH 0.99 (0.98, 1.01)
Ferritin 1.00 (0.99, 1.01)
Cholesterol 1.01 (0.99. 1.03)
TG 1.00 (0.99, 1.01)
Blood sugar 1.00 (0.99, 1.01)
Cr 0.76 (0.54, 1.07)
Uric Acid 0.74 (0.31, 1.76)
Ca 1.54 (0.56, 4.25)
P 0.45 (0.19, 1.05)
Ca×P 0.94 (0.87, 1.02)
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which we found increased the risk of PAD can be modi-
fied by life style changes. A recent review of PAD noted
the importance of risk-factor modification and appropri-
ate pharmacological management for management of
PAD [21]. Interestingly, a recent study of PAD in a
multi-ethnic Asian population reported that pulse
pressure, renal impairment, and a past history of stroke
(in addition to traditional risk factors) were important
determinants of PAD [22].Conclusions
The present retrospective study of Taiwanese ESRD
patients from a single center indicated that the overall
prevalence of PAD was 18.2%. The prevalence of PAD
was greater in the HD group than the PD group, pre-
sumably because the PD group was younger and had a
lower prevalence of diabetes mellitus. The risk factors
associated with PAD were increased age, diabetes melli-
tus, longer duration of dialysis, low serum creatinine,
hyperlipidemia, and elevated serum ferritin. Most of the
risk factors for PAD were specific to HD, and no ana-
lyzed factor was significantly associated with PAD in PD
patients.
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